None the less, our data suggest that clinically available MPL, CpG, vaccines, or perhaps a recombinant human OX40 ligand or CD40 ligand could be used to safely activate the innate system [39, 47–49], thereby enhancing the infused tumor-reactive lymphocytes [50, 51]. This evidence concerns the gene CD40LG and neoplasm.